Skip to Main Content
Contribute Try STAT+ Today

The experimental drug known as aducanumab has long been seen as the next big hope on the horizon for Alzheimer’s patients — but that hope came crashing down on Thursday, when developer Biogen announced that it was halting two late-stage studies of the treatment after an interim analysis showed it was unlikely to work.

Other companies, though, are moving forward with experimental drugs of their own. Some target those familiar amyloid plaques and tau tangles, others look to inflammation and synapse regeneration, and still another mines young blood in search of therapeutic effect.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • And let’s not forget Quincy Biosciences with their memory drug originally discovered in jellyfish. (cough)

Comments are closed.